Sequential Immunotherapy and Targeted Therapy Shows OS Benefit in BRAF+ Melanoma
Source: Targeted Oncology, October 2022
Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.
Findings from the phase 2 SECOMBIT trial (NCT02631447) show sequential immunotherapy of ipilimumab (Yervoy) plus nivolumab (Opdivo) followed by the targeted therapy combination of encorafenib (Braftovi) plus binimetinib (Mektovi) provides overall survival (OS) benefit in patients with untreated BRAF-mutated metastatic melanoma.
The randomized, 3-arm, phase 2 SECOMBIT trial enrolled patients to arm A where they were treated with targeted therapy followed by immunotherapy, arm B consisting of immunotherapy followed by targeted therapy, or arm C which gave patients targeted therapy, then immunotherapy, followed by additional targeted therapy.